These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 19450125)
21. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091 [TBL] [Abstract][Full Text] [Related]
22. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy. Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675 [TBL] [Abstract][Full Text] [Related]
23. Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms. Deng B; Jia L; Tan H; Lou Y; Li X; Li Y; Yu L J Tradit Chin Med; 2017 Feb; 37(1):35-42. PubMed ID: 29956901 [TBL] [Abstract][Full Text] [Related]
24. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128 [TBL] [Abstract][Full Text] [Related]
25. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events]. Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029 [No Abstract] [Full Text] [Related]
26. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Hu ZY; Yu Q; Zhao YS Eur J Cancer; 2010 Jul; 46(10):1856-65. PubMed ID: 20335017 [TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Innocenti F; Ratain MJ Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208 [TBL] [Abstract][Full Text] [Related]
28. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Palomaki GE; Bradley LA; Douglas MP; Kolor K; Dotson WD Genet Med; 2009 Jan; 11(1):21-34. PubMed ID: 19125129 [TBL] [Abstract][Full Text] [Related]
29. [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms]. Li H; Huang H; Liu JH Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):888-91. PubMed ID: 22333276 [TBL] [Abstract][Full Text] [Related]
32. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135 [TBL] [Abstract][Full Text] [Related]
33. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Xu C; Tang X; Qu Y; Keyoumu S; Zhou N; Tang Y Cancer Chemother Pharmacol; 2016 Jul; 78(1):119-30. PubMed ID: 27220761 [TBL] [Abstract][Full Text] [Related]
34. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. Schulz C; Heinemann V; Schalhorn A; Moosmann N; Zwingers T; Boeck S; Giessen C; Stemmler HJ World J Gastroenterol; 2009 Oct; 15(40):5058-66. PubMed ID: 19859999 [TBL] [Abstract][Full Text] [Related]
35. [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer]. Teruya T; Nakachi A; Shimabukuro N; Toritsuka D; Azuma Y; Hanashiro K; Nishiki T; Ota M; Shimabuku M; Shiroma H Gan To Kagaku Ryoho; 2015 May; 42(5):585-9. PubMed ID: 25981652 [TBL] [Abstract][Full Text] [Related]
36. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients. Peng H; Duan Z; Pan D; Wen J; Wei X Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724 [TBL] [Abstract][Full Text] [Related]
37. Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients. Yan L; Wang XF; Wei LM; Nie YL; Liu JY; Zhang LR Int J Clin Pharmacol Ther; 2016 Mar; 54(3):193-9. PubMed ID: 26857783 [TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics and irinotecan therapy. Hahn KK; Wolff JJ; Kolesar JM Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741 [TBL] [Abstract][Full Text] [Related]
39. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Rouits E; Boisdron-Celle M; Dumont A; Guérin O; Morel A; Gamelin E Clin Cancer Res; 2004 Aug; 10(15):5151-9. PubMed ID: 15297419 [TBL] [Abstract][Full Text] [Related]
40. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Schulz C; Boeck S; Heinemann V; Stemmler HJ Anticancer Drugs; 2009 Nov; 20(10):867-79. PubMed ID: 19770637 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]